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Background: Asthma patients exhibit an increased rate of loss of lung function.
Determinants to such decline are largely unknown and the modifying effect of steroid
therapy is disputed. This cross-sectional study aimed to elucidate factors contributing to
such decline and the possible modifying effect of steroid treatment.
Methods: We analyzed determinants of lung function and airway hyperresponsiveness
(AHR) in a Scandinavian study of 2390 subjects from 550 families. Families were selected
for the presence of two or more asthmatic children as part of a genetic study, Scandinavian
Asthma Genetic Study (SAGA).
Results: The primary analysis studied the association between the lung function and delay
of inhaled corticosteroids (ICS) after asthma diagnosis among asthmatic children and young
adults with a history of regular ICS treatment (N ¼ 919). FEV1 percent predicted (FEV1%
pred) was 0.25% lower per year of delay from diagnosis until treatment (p ¼ 0.039). This
association was significantly greater in allergy skin prick test negative children. There was
no significant influence of gender, age at asthma onset, or smoking.Elsevier Ltd. All rights reserved.
7 7363; fax: +45 3977 7129.
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H. Bisgaard et al.1478In the secondary analysis of the whole population of 2390 asthmatics and non-asthmatics,
FEV1% pred was inversely related to having asthmatic siblings (7.9%; po0.0001), asthma
diagnosis (2.7%; p ¼ 0.0007), smoking (3.5%; p ¼ 0.0027), and positive allergy skin
prick test (0.47% per test; p ¼ 0.012), while positively related to being of female gender
(1.8%; p ¼ 0.0029). Risk of AHR was higher by having asthmatic siblings (OR 2.7;
po0.0001), being of female gender (OR 2.0; po0.0001), and having asthma (OR 2.0;
po0.0001).
Conclusions: These data suggest that lung function is lower in asthmatics with delayed
introduction of ICS therapy, smoking, and positive allergy skin prick test. Lung function is
lower and AHR higher in female asthmatics and subjects with asthmatic siblings or
established asthma.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Asthma patients with persistent symptoms may suffer loss in
lung function from childhood.1,2 Observational data from
children3,4 and adults5,6 and one randomized controlled trial
(RCT) in newly diagnosed adult asthmatics7 suggested that
early intervention with inhaled corticosteroid (ICS) therapy
has a disease modifying effect on the long-term outcome of
lung function maintaining better pre-bronchodilator lung
function if started shortly after symptom debut. However,
recent RCTs in schoolchildren8 and preschool children9–11
were unable to confirm such disease modifying effect from
early steroid treatment.
We performed a cross-sectional observational study of
lung function and airway hyperresponsiveness (AHR) in a
Scandinavian population of 2390 subjects from 550 families
with at least two asthmatic siblings, who were recruited for
a study in asthma genetics. We hypothesized an association
between delay of therapy with ICS after asthma diagnosis
and lower lung function. We also report a secondary analysis
of the impact of asthma, heredity, allergy, gender, smoking,
and onset of asthma on lung function level and AHR in this
population.
Methods
Subjects
The subjects were part of a study on asthma genetics
comprising Caucasian families with at least two children
aged 6–36 years with a clinical asthma diagnosis. At least
one of the siblings had to be treated regularly with
glucocorticosteroids or cromones for at least 1 year or two
consecutive seasons prior to recruitment. All asthmatic
children together with their parents (less than 66 years) and
any siblings aged 6–35 years were included in the study.
Subjects suffering from cancer, heart disease, mental
retardation, or a chronic pulmonary disease other than
asthma were excluded. The children were excluded if they
were born before 34 weeks’ gestation. Families in which
both parents had ever been affected by asthma or COPD or
were currently affected by perennial or seasonal rhinitis
were also excluded from the study.
Subjects were recruited mainly from outpatient clinics at
secondary and tertiary referral pediatric and adult pulmonaryhospital departments, through publicity campaigns and
contact with patient support groups. The phenotyping was
performed in 10 centers: two in Denmark (Copenhagen,
Kolding), three in Norway (Oslo, Bergen, Trondheim/
Harstaad), and five in Sweden (Gothenburg, Lund, Stockholm,
Uppsala, Lulea˚).
The study was approved by the Ethics Committee at each
institution.
Lung function was measured on a pneumotachograph
(Vitalograph 2120, Vitalograph Ltd., Buckingham, UK (C, K)
or (Masterscope Pneumoscreen, Erich Jaeger Gmb, Essen
Germany (T, O)). The measurements were performed in
accordance with ATS guidelines.12 The subjects were tested
sitting, and wearing nose clips. Three acceptable flow–
volume curves were obtained with less than 0.2-L difference
between the largest and the second largest. The higher of
the two was used as the outcome. FEV1 was corrected for
age and height with sex-specific regression equations to
obtain percent predicted. Reference values according to
Zapletal et al.13 was used for children and Quanier14 for
adults.
Methacholine challenge test was performed by a tidal-
volume-triggered dosimetric method15 using the Spira
Elektro 2 (Respiratory Care Centre, Ha¨meenlinna, Finland),
administered to all subjects whose baseline FEV1 was
above 65% predicted and absolute FEV1 was X1.5 L (adults
only). The subjects were required not to have had
a viral respiratory infection or significant asthma exacerba-
tion requiring oral steroids during the 2 weeks preceding
the test. Baseline FEV1 was determined after saline
inhalation. Methacholine was inhaled in successively
increasing doses at 2-min intervals until FEV1 decreased
by 20% compared to baseline or a cumulative dose of
5825 mg has been given. In adults, the dose was given
in six, and in children nine incremental dose steps.
The latter schedule was implemented after an initial pilot
study on 22 children 6–16 years old at the Copenhagen
center.
At the end of the challenge test, subjects received 1.0mg
of terbutaline sulfate (Bricanyl Turbuhaler), and FEV1 was
determined 30min later to ensure its recovery to the
baseline value. AHR was analyzed as a dichotomized
variable (720% fall in FEV1 within the dose range tested).
In addition, PD20 value (mmol) was calculated by linear
interpolation between the dose points bracketing the 20%
fall in FEV1
16 and was analyzed as a continuous variable.
ARTICLE IN PRESS
Determinants of lung function and AHR in asthmatic children 1479A more detailed methodological description is provided in
Appendix A (on-line).
Skin prick tests were performed at the antebrachium of
all individuals with a standard panel of allergens; dog, cat,
horse, Dermatophagoides farinae, Dermatophagoides pter-
onyssinus, grass pollen mix, tree pollen mix, mugwort ,
Alternaria, and Cladosporium (Solupricks SD, ALK AB).
Histamine (10mg/mL) was used as a positive control and the
diluent used for the allergens as the negative control. This
outcome was analyzed as a numeric variable summarizing
the number of positive tests (0–10).
Allergen-specific IgE was assayed by a Phadiatopsmethod
with a mixture of the inhalant allergens used for skin prick
testing. The test outcome was dichotomized into positive or
negative for analysis.
Medical history was obtained by qualified doctors or
research nurses from personal interviews based on standar-
dized questionnaires with close-end response categories.
History emphasized asthma history (age when the doctor
diagnosed asthma and age at the start of ICS treatment) in
addition to current or passive smoking.
Statistical analysis
Siblings with asthma requiring prophylactic therapy for at
least 1 year were analyzed in a multiple linear regression
model describing FEV1 percent predicted (FEV1% pred) by
variables considered related to lung function and/or ICS
delay. In order not to mask the association between ICS
delay and lung function, care was taken not to include
variables that could be affected by ICS delay and at the
same time could affect FEV1% pred themselves, e.g.,
hyperreactivity. The initial model included: ICS delay, skin
prick test, allergen-specific serum IgE, gender, asthma
debut, smoking, and passive smoking.
All subjects were analyzed in a multiple linear regression
model describing FEV1% pred by variables considered
possibly related to lung function, including sibling with
asthma, skin prick test, allergen-specific serum IgE, gender,
asthma, smoking, passive smoking, and AHR.
All subjects were subsequently analyzed by a logistic
regression model describing AHR by variables considered
possibly related to AHR including sibling with asthma, skin
prick test, allergen-specific serum IgE, gender, asthma,
smoking, passive smoking, and FEV1% pred. In addition, a
multiple linear regression model describing PD20 included
the same variables.
Because individuals within a family are correlated both
due to genetic and environmental similarities, we adjusted
for this familial correlation using Proc Gen Med in SAS
version 7.0. This appropriately reduces statistical signifi-
cance based solely on the family correlation.
Results
Demographics (Table 1)
The total study comprised 550 families with 2390 individuals
(53% males). Allocation to the study was unevenly distributed
among centers and among the three Scandinavian countries:
Denmark: 455 subjects (Copenhagen), 455 (Kolding); Sweden:235 (Stockholm), 190 (Uppsala), 170 (Lulea˚), 165 (Gothen-
burg), 88 (Lund), Norway: 232 (Bergen), 203 (Trondheim), 197
(Oslo).
Primary study group comprised the 919 children with
clinical asthma treated with prophylactic asthma therapy
for at least 1 year before inclusion or for at least two
consecutive seasons. AHR was found in 83% of these
subjects. Mean FEV1 was 89% predicted. Sixty-five percent
had positive skin prick test and positive allergen-specific
serum IgE. Mean age of asthma debut was 3 years.
Secondary study group comprised all subjects (2390
individuals) including 1321 siblings (1136 with doctor-
diagnosed asthma) and 1069 parents (225 with doctor-
diagnosed asthma).
Lung function
Asthmatic siblings on regular ICS treatment: FEV1% pred was
negatively related to ICS delay among asthmatic siblings
(0.25% per year; p ¼ 0.039) (Fig. 1). Skin prick test,
antigen-specific serum IgE, gender, smoking, and age at
asthma debut did not add significantly to the asthmatic
model. This association was significantly greater in skin test
negative children (p ¼ 0.0092).
All subjects: FEV1% pred was negatively related to having
an asthmatic sibling (7.9%; po0.0001), asthma (2.7%;
p ¼ 0.0007), smoking (3.5%; p ¼ 0.0027), and positive skin
prick test (0.47% per test; p ¼ 0.012) (Fig. 2), while
positively related to being of female gender (1.8%;
p ¼ 0.0029). Passive smoking and allergen-specific serum
IgE did not add significantly to the model.
The effect of age and asthma among siblings on FEV1%
pred is depicted in Fig. 3A and B. Lung function in non-
asthmatic siblings was higher with increasing age
(p ¼ 0.0001), while no such relation was present in siblings
with an asthma diagnosis (p ¼ 0.20). This effect was not
gender specific (data not shown).
AHR
Risk of higher AHR was enhanced by being a sibling of an
asthmatic (OR 2.7; po0.0001), being female (OR 2.0;
po0.0001), and having asthma (OR 2.0; po0.0001). Active
smoking, passive smoking, positive skin prick test, allergen-
specific serum IgE, and FEV1% pred did not add significantly
to the model.
Analysis of AHR was repeated for PD20 with similar results.
Discussion
Pre-bronchodilator FEV1 was 0.25% lower per year between
asthma diagnosis and start of ICS treatment. The data did
not allow an accurate estimate of the association of lung
function and time after initiation of ICS because we do not
know for how long the ICS treatment was maintained after
initiation, but the data suggest an association between late
introduction of ICS and lower lung function. This finding
aligns with previous observational data from children3,4 and
adults5,6 as well as one RCT in adult asthmatics,7 suggesting
a disease modifying effect on pre-bronchodilator lung
function if started shortly after symptom debut. However,
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Table 1 Demographic data for subjects in a family-based study of asthma genetics.
All Asthmatic siblings with a history of regular
anti-inflammatory treatment
N Number of subjects (males) 2390 (1278) 919 (533)
Age Years (median) 24 12
Height cm (median) 167 154
Asthma Number with doctor diagnosis 1361 (57%) 919 (100%)
Asthma debut Years (median) 12 3
ICS delay Years (median) NA 3
Smoking Number (%) 340 (14%) 49 (5%)
Passive smoking Number (%) 616 (25%) 225 (24%)
Positive SPT Number (%) 1199 (50%) 593 (65%)
Positive RASTy Number (%) 1130 (47%) 586 (64%)
Positive AHRz Number (%) of positive 1631 (68%) 761 (83%)
FEV1%pred % (Mean (95% CI)) 94 (94; 95) 89 (88; 90)
Skin prick test.
yAntigen-specific IgE.
zAirway hyperresponsive to metacholine.
Figure 1 FEV1% predicted in siblings with asthma related to
time before regular ICS treatment was started.
Figure 2 FEV1% predicted in all subjects related to number of
positive skin prick tests.
H. Bisgaard et al.1480recent RCTs in schoolchildren8 and preschool children9–11
were unable to confirm such disease modifying effect from
early steroid treatment. The disparate outcomes may be
ascribed to fundamental differences in study designs or may
be compatible with a treatment effect later in life affecting
the natural decline in lung function while not apparent
during childhood growth, or it may be due to differences in
asthma severities.
The protective effect from ICS on lung function loss is
small according to the current study (0.25% per year). It is
questionable whether a 2.5% reduction of FEV1 for a 10-year
delay in ICS treatment will have any clinical consequences
for the young asthmatics in adulthood.
Age at asthma onset showed no relation to lung function.
Early onset of asthma has been associated with a negativeoutcome4,17,18 or no effect.19,20 A recent large cross-
sectional pediatric cohort study of asthma revealed an
independent relationship between asthma duration and
asthma severity.4 The lack of evidence for such an
association in the present study does not contradict this
recent report.
Analyses of the secondary study group of asthmatics and
their non-asthmatic siblings and parents showed that FEV1%
pred was most strongly influenced by membership in the
sibling group independent of an asthma diagnosis. Siblings of
asthmatics had 7.9% lower FEV1% pred and a 2.7-fold greater
AHR. The lower lung function in siblings was clearly more
pronounced in the younger age group.
Smoking was associated with an additional 3.5% reduction
in FEV1% pred in the secondary study group of asthmatics
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Figure 3 FEV1% predicted related to sibling status and age.
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cohort study with a 15-year follow-up, which showed that
smoking contributed significantly to the decline in lung
function in both asthmatics and non-asthmatics.1 Previous
smaller reports were unable to demonstrate this additive
effect of asthma and smoking.21,22
Allergy as reflected in positive skin prick tests was
a significant predictor of lower lung function in the
secondary study group. This finding is consistent with
some previous longitudinal studies,23,24 though not with
others,25–27 as positive skin prick tests have even been found
to predict a milder course.20 Allergen-specific serum IgE did
not add significantly to the models describing lung function
and AHR.
Being a female doubled the risk of AHR but provided a
small but significantly higher lung function. Female gender
was a marker of a worse prognosis in some studies,18,28–30
though this was not apparent in other studies22,26,31 and one
study even reported a better prognosis for females.32 That
female gender is a predictor of a worse prognosis finds
support in the observation that estrogen plays a role in
asthma pathophysiology.33
Certain issues should be considered when the present
data are interpreted. The study was cross-sectional and
observational. The cohort had an inherent selection bias as
subjects were only included if they belonged to families
with at least two siblings with asthma as the study primarily
aimed at genetic analyses. Recall bias could confound such
retrospective collection of the time of onset of symptoms
and start of ICS treatment, and we had no access to source
data documenting asthma debut. Limitations include the
small number of non-asthmatic siblings, which limit our
ability to comment in detail on asthma development. On the
other hand, the data quality was high since rigorous quality
assurance was ensured and monitored in all centers,
objective measurements were obtained through highly
standardized methods and qualified doctors or research
nurses obtained the data on asthma history from personal
interviews based on standardized questionnaires with close-
end response categories. Finally, the power of the study was
high because of the large cohort size and the long age span.
Therefore, we believe that the conclusions of the analyses
are quite robust.
In conclusion, the study suggests that lower lung function
is associated with delayed introduction of ICS therapy. Lungfunction is lower and AHR higher in subjects with asthmatic
siblings, females and subjects with established asthma.
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